Mutations in class I, which includes nonsense or premature stop codon (PTC) mutations [4], some of which are among the most common mutations in CF, have been largely bypassed by the recently approved CFTR corrector therapies [19]. The gene discussed is CFTR; the disease is cystic fibrosis.